/
/
New Drug for Myeloma Targeting Myeloma Cell Survival Pathway
New Drug for Myeloma Targeting Myeloma Cell Survival Pathway image
New Drug for Myeloma Targeting Myeloma Cell Survival Pathway
Posted Nov 06, 2018

A new pathway to stop myeloma progression is being studied with a new drug, according to a recent report by UK multiple myeloma specialists. 

A pathway that helps myeloma cells survive, called nuclear factor (NF)‐κB, is activated in all cases of multiple myeloma. Many companies have tried to target this pathway over the last 30 years with no success due to potential toxicities of the approach. The authors state: 

"Therefore, there is a need for a fresh approach to safely block NF‐κB signaling in MM."

The researchers developed a new drug called DT3 that was tested in an early Phase I/2a clinical trial. The drug, called DTP3, goes downstream to stop two players of the NF‐κB pathway from binding together, allowing them to let the myeloma cells die. 

The study included three patients who had progressive disease after multiple prior myeloma treatments. All three patients finished their 28-day treatment cycle without complications. There were no reportable side effects of concern. The second patient who was on the highest dose saw their M-protein and light chains decrease and they stayed on the treatment for a total of three 4‐week treatment cycles (3 months) before developing progressive disease. 

The other patients may have not responded because they did not have the GADD45b protein present. The researchers propose that testing could be performed to indicate the presence of GADD45b in order to know who may respond to DTP3. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811